Fibronectin-Expressing Mesenchymal Tumor Cells Promote Breast Cancer Metastasis.
breast cancer
cell migration tracking
epithelial mesenchymal transition
extracellular matrix
fibronectin
metastasis
microfluidics
plasticity
premetastatic niche
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
08 Sep 2020
08 Sep 2020
Historique:
received:
15
07
2020
revised:
27
08
2020
accepted:
02
09
2020
entrez:
11
9
2020
pubmed:
12
9
2020
medline:
12
9
2020
Statut:
epublish
Résumé
Tumor metastasis is connected to epithelial-mesenchymal heterogeneity (EMH) and the extracellular matrix (ECM) within the tumor microenvironment. Mesenchymal-like fibronectin (FN) expressing tumor cells enhance metastasis within tumors that have EMH. However, the secondary tumors are primarily composed of the FN null population. Interestingly, during tumor cell dissemination, the invasive front has more mesenchymal-like characteristics, although the outgrowths of metastatic colonies consist of a more epithelial-like population of cells. We hypothesize that soluble FN provided by mesenchymal-like tumor cells plays a role in supporting the survival of the more epithelial-like tumor cells within the metastatic niche in a paracrine manner. Furthermore, due to a lower rate of proliferation, the mesenchymal-like tumor cells become a minority population within the metastatic niche. In this study, we utilized a multi-parametric cell-tracking algorithm and immunoblotting to evaluate the effect of EMH on the growth and invasion of an isogenic cell series within a 3D collagen network using a microfluidic platform. Using the MCF10A progression series, we demonstrated that co-culture with FN-expressing MCF10CA1h cells significantly enhanced the survival of the more epithelial MCF10CA1a cells, with a two-fold increase in the population after 5 days in co-culture, whereas the population of the MCF10CA1a cells began to decrease after 2.5 days when cultured alone (
Identifiants
pubmed: 32911713
pii: cancers12092553
doi: 10.3390/cancers12092553
pmc: PMC7565075
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : R00 CA198929
Pays : United States
Organisme : American Cancer Society
ID : RSG-16-172-01-CSM
Organisme : Indiana Clinical and Translational Sciences Institute
ID : UL1TR002529
Organisme : NCI NIH HHS
ID : R00CA198929
Pays : United States
Références
J Clin Invest. 2010 Jun;120(6):1800-3
pubmed: 20501952
Cancers (Basel). 2020 May 17;12(5):
pubmed: 32429591
Ann Oncol. 2010 Oct;21 Suppl 7:vii89-92
pubmed: 20943648
J Biol Chem. 2013 Jun 21;288(25):17954-67
pubmed: 23653350
J Clin Oncol. 2009 Mar 10;27(8):1160-7
pubmed: 19204204
J Exp Med. 1962 Mar 1;115:453-66
pubmed: 13872176
Cell Cycle. 2009 Sep 15;8(18):2901-6
pubmed: 19713745
J Struct Biol. 2005 Aug;151(2):182-95
pubmed: 16043363
Sci Rep. 2017 Apr 21;7(1):1075
pubmed: 28432337
Eur J Histochem. 2017 May 31;61(2):2783
pubmed: 28735522
Int J Radiat Oncol Biol Phys. 1988 May;14(5):947-55
pubmed: 3360660
J Cell Sci. 1991 Aug;99 ( Pt 4):769-75
pubmed: 1770004
Cancer Res. 2019 Jun 15;79(12):3011-3027
pubmed: 31053634
Mol Cancer Res. 2018 Oct;16(10):1579-1589
pubmed: 29934326
Cancer Res. 2007 Dec 15;67(24):11471-5
pubmed: 18089772
Semin Cancer Biol. 1995 Jun;6(3):165-73
pubmed: 7495985
PLoS One. 2019 Jul 17;14(7):e0219708
pubmed: 31314801
BMC Cell Biol. 2011 May 18;12:21
pubmed: 21592329
IEEE Trans Pattern Anal Mach Intell. 1986 Jun;8(6):679-98
pubmed: 21869365
PLoS One. 2013 Sep 27;8(9):e76220
pubmed: 24086712
Oncogene. 2011 Nov 17;30(46):4609-21
pubmed: 21643013
Nat Rev Cancer. 2018 Feb;18(2):128-134
pubmed: 29326430
J Cell Biol. 1977 Nov;75(2 Pt 1):606-16
pubmed: 264125
J Clin Oncol. 2012 Feb 20;30(6):593-9
pubmed: 22124109
Dev Cell. 2008 Jun;14(6):818-29
pubmed: 18539112
Nature. 2007 Oct 4;449(7162):557-63
pubmed: 17914389
J Clin Invest. 2011 Oct;121(10):3786-8
pubmed: 21965334
Oncogenesis. 2020 Feb 13;9(2):16
pubmed: 32054828
Sci Rep. 2015 Oct 01;5:14580
pubmed: 26423227
Nat Rev Cancer. 2009 Apr;9(4):274-84
pubmed: 19308067
Nat Methods. 2017 Dec;14(12):1141-1152
pubmed: 29083403
Breast Cancer Res. 2011 Aug 12;13(4):215
pubmed: 21884641
Nat Immunol. 2010 Apr;11(4):313-20
pubmed: 20190758
PLoS One. 2012;7(12):e50804
pubmed: 23251387
CA Cancer J Clin. 2014 Jan-Feb;64(1):52-62
pubmed: 24114568
Methods Mol Biol. 2011;769:191-203
pubmed: 21748677
Oncogene. 2014 Mar 27;33(13):1649-57
pubmed: 23624917